

85689.docx

Polyposis found on index colonoscopy in a 56-year-old female: A case report on a *BMPR1A* variant in juvenile polyposis syndrome

BMPR1A variant in juvenile polyposis syndrome

Michael Yulong Wu, Christopher Toon, Michael Field, May Wong

Abstract**BACKGROUND**

Juvenile polyposis syndrome (JPS) is a rare hereditary polyposis disease frequently associated with an autosomal-dominant variant of the *SMAD4* or *BMPR1A* gene. It often manifests with symptoms in children and adolescents and is infrequently diagnosed in asymptomatic adults. Establishing the diagnosis is important as patients with JPS have a high risk of developing gastrointestinal cancer and require genetic counselling and close routine follow-up.

CASE SUMMARY

We report on the case of a 56-year-old female diagnosed with juvenile polyposis syndrome after genetic testing revealed a rare variant of the *BMPR1A* gene *BMPR1A c.1409T>C* (p.Met470Thr). She was initially referred for colonoscopy by her general practitioner after testing positive on a screening faecal immunochemical test and subsequently found to have polyposis throughout the entire colorectum on her index screening colonoscopy. The patient was asymptomatic with a normal physical examination and no related medical or family history. Blood tests revealed only mild iron deficiency without anemia. To date, there has only been one other reported case of JPS

with the same genetic variant. Subsequent colonoscopies were organised for complete polyp clearance and the patient was returned for surveillance follow-up.

CONCLUSION

JPS patients can present with no prior symptoms or family history. Genetic testing plays an important diagnostic role guiding management.

Key Words: Juvenile polyposis syndrome; Polyps; Colorectal polyp; Hereditary polyposis; Cancer; Case report

Wu MY, Toon C, Field M, Wong M. Polyposis found on index colonoscopy in a 56-year-old female: A case report on a BMPR1A variant in juvenile polyposis syndrome. *World J Gastrointest Endosc* 2023; In press

Core Tip: Juvenile polyposis syndrome (JPS) is a hereditary autosomal dominant disease that phenotypically presents with polyposis throughout the colorectum. Detection and diagnosis is important as patients have a high risk of developing gastrointestinal cancer. Symptoms often manifest in childhood and adolescence with most having evidence of an associated family history. We report a case of polyposis found on index screening endoscopy in an asymptomatic female with no prior related family or medical history. Subsequent genetic testing led to the diagnosis of JPS after detecting a rare variant of the *BMPR1A* gene previously only reported in one other case of JPS.

INTRODUCTION

Hereditary gastrointestinal polyposis syndromes are a rare group of diseases that account for up to approximately 5% of all colorectal cancers ¹. These polyposis syndromes are broadly categorised based on whether polyps demonstrate predominantly adenomatous or hamartomatous changes. Hamartomatous polyposis syndromes include Peutz-Jeghers Syndrome, PTEN hamartomatous syndromes (Cowden Syndrome and PTEN-related

Proteus Syndromes) and Juvenile Polyposis Syndrome (JPS) ². Early recognition and detection of these hereditary diseases is important due to the lifetime risk of developing gastrointestinal cancer. JPS often manifests with gastrointestinal symptoms such as rectal bleeding, anemia, bowel habit changes and abdominal pain in childhood with an average age of diagnosis in the adolescent years ^{3,4}. We present a case of a patient with polyposis found on index screening endoscopy and discovery of a rare de novo variant of the *BMPR1A* gene on genetic testing leading to the subsequent diagnosis of JPS. This is a unique presentation of an asymptomatic adult with no related medical or family history and to date, there has been only one other reported case of JPS with the same genetic variant. This case highlights the importance of clinician vigilance as many individuals may present with no related history and emphasises the need for early genetic testing to guide appropriate management and surveillance intervals.

CASE PRESENTATION

Chief complaints

A 56-year-old female was referred in by her general practitioner after she tested positive on screening faecal immunochemical test (FIT).

History of present illness

She reported some infrequent constipation but no acute bowel habit changes. Overall, she was constitutionally well with no history of abdominal pain, malaena, haematochezia, or weight loss.

History of past illness

She had a medical history of gastroesophageal reflux disease and asthma. Her only regular medication was a budesonide-formoterol (200mcg/6mcg) inhaler.

Personal and family history

1 She had no history of smoking or alcohol use. There was no family history of colorectal cancer or other gastrointestinal diseases.

Physical examination

The patient was fit and well with normal vital signs. There were no significant findings on physical examination such as skin lesions commonly associated with Cowden and other PTEN hamartoma syndromes, mucosal pigmentation associated with Peutz-Jeghers syndrome and macrocephaly associated with JPS ⁵⁻⁷. There were no features of alopecia, onychodystrophy or hyperpigmentation that may be seen in Cronkhite-Canada syndrome ⁸. She had no features of Hereditary Haemorrhagic Telangiectasia (HHT) typically seen in *SMAD4* juvenile polyposis.

Laboratory examinations

The only abnormalities on her blood tests were a mild iron deficiency with ferritin level 25 µg/L (reference range 30 – 300 µg/L) without anaemia.

Imaging examinations

The patient proceeded to a gastroscopy which found a single medium-sized fundic gland polyp and a colonoscopy demonstrating more than one hundred pedunculated polyps throughout **1** the caecum, ascending colon, transverse colon, descending colon, sigmoid colon, rectosigmoid colon and rectum (Figure 1). Initial biopsies were taken throughout the gastrointestinal tract and several larger polyps were removed for histology. A CT enterography of the small bowel did not show any small bowel polyps.

Further Diagnostic Work-up

On histology, the polypoid colonic mucosa showed epithelial-stromal hamartomatous features with variable epithelial hyperplasia and subtle myofibroblastic proliferation in the lamina propria (Figure 2). Overall features were consistent with a hamartomatous polyposis syndrome. Juvenile polyposis syndrome, Peutz-Jegher syndrome, Cronkhite-

Canada syndrome and Cowden syndrome were considered differential diagnoses however sub-classification proved difficult as there were no further distinguishing histological features ^{9,10}.

The patient was referred for multi-gene panel testing which included *STK11* associated with Peutz-Jeghers Syndrome, *PTEN* associated with PTEN hamartoma syndromes (Cowden syndrome and PTEN-related Proteus Syndromes) and *SMAD4* and *BMPR1A* associated with JPS. Massively Parallel Sequencing of >99% of the coding sequences including the exon/intron boundaries to a depth of >200x was performed to generate this result. SOPHiA genetics DDM (Sophia Genetics, Saint-Sulpice, Switzerland) was used to generate aligned reads and call variants against the hg19 human reference genome. A rare variant of *BMPR1A* written as *BMPR1A c.1409T>C* (p.Met470Thr) was identified and JPS was diagnosed as the likely cause of her polyposis phenotype. The patient has three siblings and one surviving parent none of whom have a history of colorectal cancer or polyps. All bar one of these relatives lives overseas. The patient's 35 year old son subsequently underwent a colonoscopy which showed no polyps. Genetic testing was also offered to the son which returned negative for the *BMPR1A* variant.

FINAL DIAGNOSIS

The combination of colonoscopy findings, histopathology and multi-gene panel testing led to the diagnosis of juvenile polyposis syndrome.

TREATMENT

Three subsequent colonoscopies were organised for complete polyp clearance and histopathology demonstrated similar hamartomatous polyps with some showing early adenomatous changes.

OUTCOME AND FOLLOW-UP

The patient was recommended to return for yearly colonoscopy surveillance given the initial polyp burden.

DISCUSSION

JPS is a rare autosomal dominant disease with an estimated incidence around 1/100,000 - 1/160,000 and a 39 - 68% lifetime risk of colon cancer ¹¹. Polyp growth occurs primarily in the colorectum but can also appear in the stomach and small bowel. Macroscopically JPS polyps appear as pedunculated, exophytic, shiny and spherical growths ^{2,12}. Histologically, juvenile polyps typically demonstrate dilated thick mucin-filled glands with inflammatory infiltrates in the lamina propria. Despite these features, polyps in JPS can often still be indistinguishable from other polyposis syndromes. Clinical diagnostic criteria also exist in which a diagnosis can be made with the presence of any of the following: ² >5 juvenile polyps in the colorectum, juvenile polyps in other parts of the gastrointestinal tract or any number of juvenile polyps and a positive family history ¹³. Confirmatory genetic testing is recommended for all patients meeting clinical diagnostic criteria however the presence of germline mutations may only be present in 20 - 60% of individuals ^{4,12}. Making an accurate diagnosis of JPS can remain a challenge for clinicians due to the similarity of features with other polyposis syndromes and a lack of a clear 'gold standard' diagnostic. In our case, a diagnosis was made on the basis of polyp morphology, histology and confirmatory genetic testing.

The heterozygous *BMPRI1A* c.1409T>C (p.Met470Thr) variant is a missense mutation of Methionine to Threonine and identified only in one other patient with JPS ¹⁴. In silico analysis predicted the variant affects protein function. Based on a lack of functional proof and biological information that the variant was damaging, the variant was ³ classified as a variant of unclear significance (class 3) according to the American College of Medical Genetics and Genomics-Association for Molecular Pathology SHERLOC (semiquantitative, hierarchical evidence-based rules for locus interpretation) guidelines ¹⁵. Whilst 45% to 60% of JPS cases are attributed to more common disease-causing variants in

either the *BMPR1A* or *SMAD4* gene, there are still a number of cases without an identifiable pathogenic variant¹⁶. Since the variant is absent in a large population control group (gnomAD), has been previously reported in a patient with JPS and showed limited segregation with disease in this family, the *BMPR1A* c.1409T>C (p.Met470Thr) variant was considered by the authors to be the likely cause of the patients phenotype¹⁷. Given the rarity of disease, reporting on the polyposis features of this patient diagnosed with JPS contributes to the growing body of knowledge on the pathogenicity of *BMPR1A* variants.

The role of genetic counselling is invaluable in the management of a patient with JPS. Around 50% of individuals with JPS will have affected parents whilst the remaining half will have no prior family history of polyps and represent a de novo mutation¹⁸. Children of affected individuals have a 50% chance of inheritance. It is recommended that even asymptomatic relatives of individuals with JPS undergo evaluations with either genetic testing, if the gene variant is known, or endoscopic screening if the variant is unknown¹⁸. In the case of this patient, genetic screening was performed on the son to ensure early disease surveillance and monitoring.

For patients with polyposis syndrome, current guidelines by the American College of Gastroenterology (ACG) recommend screening gastroscopy and colonoscopy from age 12 or earlier if individuals are symptomatic with repeat surveillance endoscopy every 1 – 3 years depending on polyp burden⁴. The European Society of Gastrointestinal Endoscopy (ESGE) outline similar colonoscopy age intervals however recommend gastroscopy in asymptomatic individuals start at 18 years for those with a *SMAD4* mutation and at 25 years in those with *BMPR1A* mutation¹⁹. The ACG recommends removal of all polyps ≥5 mm whilst the ESGE recommends removal of those >10 mm^{4,19}. Periodic surveillance of the small bowel is recommended by the ACG however is not recommended by the ESGE given the rarity of small bowel involvement in JPS^{4,19}. Surgical management with colectomy and ileo-rectal anastomosis is recommended if

cancer, high-grade dysplasia or polyposis cannot be managed endoscopically ⁴. In our patient, serial colonoscopies at 3 moly intervals were adequate for complete polyp clearance and follow-up was organised for yearly surveillance given the significant polyp burden on initial colonoscopy. Current guidelines provide blanket recommendations to all patients diagnosed with JPS regardless of the gene-phenotype. Therefore a better understanding of the pathogenecity of gene variants can provide information that may help individualise clinical surveillance intervals.

This case highlights the presentation of an asymptomatic female found to have a rare potentially de novo variant in the *BMPR1A* gene leading to the diagnosis of JPS. This case serves as a reminder that many patients may be asymptomatic with no related medical or family history. It demonstrates the importance of referral to a geneticist for multigene panel testing for confirmatory diagnosis, guidance on further management of the patient and cancer surveillance intervals.

CONCLUSION

JPS is a rare disease that can be a challenging diagnosis to be distinguished from other hereditary polyposis syndromes. This case demonstrates that some patients may present in adulthood with no related symptoms or prior history. We describe the second reported case in literature of a rare potentially de novo variant of the *BMPR1A* gene in a patient with JPS. This report contributes to the developing body of literature and understanding in the pathogenicity of variants in *BMPR1A* gene.

Figure Legends

Figure 1 Endoscopic view. (Left) White Light Endoscopy Transverse Colon and (Right) Narrow Band Imaging Transverse colon showing pedunculated polyps in the transverse colon with some grouped into grapelike clusters.

Figure 2 Histology of ascending colon polyp.

6%

SIMILARITY INDEX

PRIMARY SOURCES

- | | | |
|----------|--|----------------------|
| 1 | www.ncbi.nlm.nih.gov
<small>Internet</small> | 40 words — 2% |
| <hr/> | | |
| 2 | Kevin J Monahan, Nicola Bradshaw, Sunil Dolwani, Bianca Desouza et al. "Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)", Gut, 2020
<small>Crossref</small> | 23 words — 1% |
| <hr/> | | |
| 3 | pure.eur.nl
<small>Internet</small> | 18 words — 1% |
| <hr/> | | |
| 4 | Elena G. Gibson, Judith Staub, Priyanka Kanth. "Endoscopic Management of Hamartomatous Polyposis Syndromes", Current Treatment Options in Gastroenterology, 2021
<small>Crossref</small> | 12 words — 1% |
| <hr/> | | |
| 5 | Myung Jin Jee, Soon Man Yoon, Eui Joong Kim, Hyun-Jung Choi et al. " A Novel Germline Mutation in Exon 10 of the Gene in a Familial Juvenile Polyposis ", Gut and Liver, 2013
<small>Crossref</small> | 12 words — 1% |
| <hr/> | | |
| 6 | f6publishing.blob.core.windows.net
<small>Internet</small> | 12 words — 1% |

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	< 12 WORDS
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 12 WORDS